JUL 08, 2021 8:40 AM PDT

Activating p53 May Boost Efficacy of Cancer Immunotherapy

WRITTEN BY: Annie Lennon

Pharmacological activation of the p53 protein in cancer cells leads to an anti-tumor immune response in lab tests. These findings, say researchers, could increase efficacy rates of immunotherapies to treat cancer. The study was published in Cancer Discovery by researchers at Karolinska Institutet in Sweden. 

For some time, scientists have known that p53 is able to prevent genome instability by silencing certain sequences in our genome known as endogenous retroviruses, elements of DNA that are inherited from viruses. 

Dubbed the ‘guardian of the genome’, the protein is thought to play a key role in inhibiting tumor growth. This comes as half of all tumors have mutations in the gene that codes for p53. Meanwhile, in many other tumors, p53 is disabled by another protein known as MDM2. 

The researchers behind the present study thus sought out to see whether pharmacologically activating p53 could affect the growth of cancer cells. To do so, they blocked MDM2 in mouse models with a substance known as ALRN-6924 from the US pharmaceutical company, Aileron Therapeutics. 

In doing so, the researchers noted that they were able to block MDM2 and activate p53. This then activated endogenous retroviruses which went on to trigger an antiviral response that boosted the production of interferons, signaling proteins that cause nearby cells to increase their anti-viral defenses. The same response was also noted in tumor samples from two patients taking part in the company’s clinical trials of ALRN-6924. 

"This shows that there are synergies that should be exploited between substances that block MDM2 and modern immunotherapies," says Galina Selivanova, lead author of the research, "A combination of these can be particularly important for patients who don't respond to immunotherapy."

Selivanova is currently researching whether a molecule known as APR-246, known as 'Eprenetapopt', can produce the same boost in interferons, and thus have the same potential to increase the efficacy of immunotherapy for patients with severe forms of cancer. 

 

Sources: Cancer DiscoveryEurekAlert

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
APR 11, 2021
Genetics & Genomics
Trial Shows Personalized Cancer Vaccines are Safe
APR 11, 2021
Trial Shows Personalized Cancer Vaccines are Safe
Vaccines are mostly known as tools to prevent illness. But cancer vaccines are a bit different, and aim to treat existin ...
MAY 18, 2021
Cancer
New guidelines change screening age for colorectal cancer to 45
MAY 18, 2021
New guidelines change screening age for colorectal cancer to 45
Following new guideline changes from the U.S. Preventive Services Task Force (USPSTF), individuals with an average risk ...
JUN 10, 2021
Clinical & Molecular DX
Algorithm Flags High Risk of Pancreatic Cancer
JUN 10, 2021
Algorithm Flags High Risk of Pancreatic Cancer
In 2021, over 60,000 individuals in the U.S. alone will be diagnosed with pancreatic cancer. Researchers are turning to ...
JUN 11, 2021
Cell & Molecular Biology
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
JUN 11, 2021
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
The immune system can detect and destroy pathogenic and cancerous cells, but sometimes those dangerous cells can evade t ...
JUN 12, 2021
Cancer
Using astronomy to image cancer tumors
JUN 12, 2021
Using astronomy to image cancer tumors
In an interdisciplinary breakthrough, a recent study published in Science describes the development of a new platform, d ...
JUL 13, 2021
Clinical & Molecular DX
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
JUL 13, 2021
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
Researchers have developed the first diagnostic “pen” that acts as a guide for surgeons, helping them distin ...
Loading Comments...